Page last updated: 2024-12-06

falipamil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

falipamil: bradycardic agent which blocks myocardial calcium channels in frequency- & voltage-dependent manner; RN given refers to parent cpd; structure given in Unlisted Drugs [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71222
CHEMBL ID1192913
SCHEMBL ID1817019
MeSH IDM0096504

Synonyms (19)

Synonym
falipamil
aq-a-39
aq-a 39
2-(3-((3,4-dimethoxyphenetyl)methylamino)propyl)-5,6-dimethoxyphthalimidine
falipamilum [inn-latin]
1h-isoindol-1-one, 2-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino)propyl)-2,3-dihydro-5,6-dimethoxy-
falipamil [inn]
77862-92-1
2-[3-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]propyl]-5,6-dimethoxy-3h-isoindol-1-one
CHEMBL1192913
falipamilum
n6a93zmn7u ,
unii-n6a93zmn7u
1h-isoindol-1-one,2-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-2,3-dihydro-5,6-dimethoxy-
DTXSID70228476
SCHEMBL1817019
Q5431893
2-(3-((3,4-dimethoxyphenethyl)(methyl)amino)propyl)-5,6-dimethoxyisoindolin-1-one
AKOS040748342

Research Excerpts

Overview

Falipamil (AQ-A 39) is a new verapamil derivative. It exerts antitachycardic effects by a direct action on the sinus node.

ExcerptReferenceRelevance
"Falipamil (AQ-A 39) is a new verapamil derivative which exerts antitachycardic effects by a direct action on the sinus node. "( Effects of falipamil (AQ-A 39) on heart rate and blood pressure in resting and exercising healthy volunteers.
Ferry, A; Hilaire, J; Jaillon, P; Lecocq, B; Lecocq, V; Maria, JF; Naudascher, M, 1989
)
2.11

Dosage Studied

ExcerptRelevanceReference
" AQA 39 shifted the dose-response curve to ionophoretic application of acetylcholine to higher concentrations, suggesting a competitive action of the drug with acetylcholine at the muscarinic receptor."( The electrophysiological basis of the bradycardic action of AQA 39 on the sinoatrial node.
Osterrieder, W; Pelzer, D; Trautwein, W; Yang, QF, 1981
)
0.26
" In isolated guinea-pig atria UL-FS 49 antagonized the carbachol-induced bradycardia; a 10-fold shift of the dose-response curve (CA10) was achieved with 11."( Cardiovascular characterization of UL-FS 49, 1,3,4,5-tetrahydro-7,8-dimethoxy-3-[3-][2-(3,4-dimethoxyphenyl)ethyl] methylimino]propyl]-2H-3-benzazepin-2-on hydrochloride, a new "specific bradycardic agent".
Kobinger, W; Lillie, C, 1984
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (52)

TimeframeStudies, This Drug (%)All Drugs %
pre-199043 (82.69)18.7374
1990's7 (13.46)18.2507
2000's2 (3.85)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (10.34%)5.53%
Reviews4 (6.90%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other48 (82.76%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]